AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TLSA · NASDAQ · Biotechnology

Tiziana Life Sciences (ADR) (TLSA)

Develops intranasal anti-CD3 immunotherapy for neuroinflammatory and neurodegenerative diseases.

$0.9990

Pre-market+0.06 (+6.48%)

At close$0.9382(−2.64%)

Watchlist

In millions of USD, except per-share figures

In millions	Q2 FY20Jun 2020	Q4 FY20Mar 2021	Q2 FY21Jun 2021	Q4 FY21Mar 2022	Q2 FY22Jun 2022	Q4 FY22Dec 2022	Q2 FY23Jun 2023	Q4 FY23Dec 2023	Q2 FY24Jun 2024	Q4 FY24Dec 2024	Q2 FY25Jun 2025	Q4 FY25Dec 2025
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0	0
	5	25	21	2	6	12	15	6	13	9	9	12
Research & development	0	3	6	4	9	7	4	5	5	3	3	7
Selling, general & administrative	2	6	15	1	−5	6	−2	1	8	6	6	5
Other expenses	3	17	0	−3	2	0	12	0	0	0	0	0
Operating income	−5	−25	−21	−5	−6	−12	−15	−6	−13	−9	−9	−12
	0	2	4	0	0	−1	4	−2	−3	0	3	0
Interest income	0	0	0	0	0	0	0	1	0	1	0	0
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	0	1	0	0	0	1	−4	2	3	0	−3	0
Income before tax	−5	−24	−17	−5	−5	−13	−11	−9	−16	−9	−6	−13
Income tax expense	0	−2	0	0	0	0	0	0	−7	−2	0	0
Net income from continuing operations	−5	−21	−17	−3	−5	−13	−11	−9	−9	−7	−6	−13
Net income	−5	−21	−17	−3	−5	−13	−11	−9	−9	−7	−6	−13
EPS, basic	−$0.07	−$0.24	−$0.24	−$28.90	−$0.10	−$0.28	−$0.20	−$0.18	−$0.18	−$0.13	−$0.10	−$0.22
EPS, diluted	−$0.07	−$0.24	−$0.24	−$28.90	−$0.10	−$0.28	−$0.20	−$0.18	−$0.18	−$0.13	−$0.10	−$0.22
Weighted average shares, basic	75	44	75	111	51	50	51	51	52	55	58	59
Weighted average shares, diluted	75	44	75	111	51	50	51	51	52	55	58	59
EBITDA	−5	−25	−21	−5	−5	−13	−11	−9	−16	−9	−6	−12
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−5	−25	−21	−5	−5	−13	−11	−9	−16	−9	−6	−12